mRNA Cancer Therapeutics Patent Landscape Report 2024

Patent Landscape Report Coverage

The mRNA Cancer Therapeutics Patent Landscape Report provides a comprehensive and in-depth analysis of the patents in this industry. The key sections captured in the report for mRNA cancer therapeutics include a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within mRNA cancer therapeutics technologies.

The COVID-19 pandemic has highlighted the need for the development of more advanced vaccines. As a result, scientists are keen to develop therapeutics and diagnostics based on mRNA technologies. Hence, patent claims are crucial for the protection of the latest inventions. This has led to an increase in the number of patent applications, impacting the patent landscape significantly.

For instance, in April 2024, Moderna announced that it had been granted a patent for a cancer treatment with a lipid nanoparticle containing mRNA encoding a tethered interleukin-12 polypeptide as its administering method. This innovative approach aims to inhibit or reduce tumor growth in patients.

mRNA Cancer Therapeutics Patent Outlook

• Innovations in delivery technologies such as lipid nanoparticles (LNPs), polymer, and immune modulation techniques are likely to be patentable as companies are trying to improve the efficacy and safety of mRNA therapies.

• Big pharmaceutical companies, biotech firms, and research and academic institutions are actively patenting mRNA technology for cancer treatment. Moreover, emerging startups are also contributing to the patent landscape as they are focusing on developing innovative approaches in mRNA technologies.

• The United States, and European countries are the most active applicants of mRNA-based vaccines. The top companies include Moderna and CureVac. They have filed patent applications for a wide range of vaccines, signifying their treatment efficiency.

What are mRNA therapeutics?

Messenger RNA or mRNA is a type of single-stranded ribonucleic acid that is transcribed from a strand of DNA. It carries the coding information for protein synthesis. The development of mRNA-based therapeutics mainly includes mRNA entrapment, mRNA design, synthesis, pharmacodynamics, pharmacokinetics, and safety evaluation in vivo and in vitro.

The successful result of COVID-19 mRNA vaccines has accelerated confidence to utilize this RNA-based technology. This has led to an increase in investment activities across the pharmaceutical industry. As more therapies move through clinical trials, patent filings are expected to increase.

For instance, with the success of the mRNA COVID- 19 vaccines, an investigational vaccine mRNA-4157-P201 received breakthrough therapy designation in 2023. Jointly developed by Moderna in combination with checkpoint inhibitor pembrolizumab (Merck), it is intended to treat high-risk melanoma.

mRNA Cancer Therapeutics Industry Growth Drivers

Surge in Research and Development Activity is Expected to Boost Patent Industry Growth

The mRNA-based therapy is expected to be useful in multiple treatments including cancer. These drugs offer the advantages of low side effects and higher efficiency.

In April 2024, a clinical trial study reported successful results using mRNA technology for pancreatic cancer treatment. The data shows that the investigational mRNA vaccine can trigger T cells (the cells that mobilize anti-tumor immune responses).

Another promising trial by The University of Cincinnati Cancer Center for a pancreatic cancer vaccine introduces a novel approach to cancer treatment. This approach uses mRNA technology which instructs the immune system to target pancreatic cancer cells by recognizing their unique genetic markers.

The development of innovative clinical approaches to treat cancer has led to patent filing by multiple companies. In August 2022, Regen Biopharma filed a p atent on an mRNA cancer immunotherapy vaccine. The patent was filed with USPTO. Hence, the increase in patent filing is impacting the patent landscape positively.

Advancements in Delivery Platform is Expected to Propel mRNA Cancer Therapeutics Patent Industry Growth

The continuous developments in mRNA synthesis and delivery technologies expand the patent landscape. The innovative developments in delivery platforms like lipid nanoparticles (LNPs), enhance the efficacy and safety of mRNA therapies.

LNP has several advantages over other delivery technologies like its ability to carry multiple mRNAs in one formulation, is minimally immunogenic, and ease of scaling up. The development of these innovative technologies impacting the patent landscape as companies are protecting their intellectual property rights.

mRNA Cancer Therapeutics Patent Segmentation

The report will cover the following sections in detail:

Breakup by Carrier

• Vesicle

• Virus

• Peptide

• Lipid

• Polymer

Breakup by Design

• Self-Amplifying mRNA

• Conventional Non-Amplifying mRNA

Breakup by Route of Administration

• Tumoral

• Parenteral

• Other

Breakup by Therapy Type

• Immunomodulator

• mRNA Encoded Antibody

• Modified Antigen Receptor

• Antigen via DC Loading

• Antigen via Direct Injection

mRNA Cancer Therapeutics Patent Segmentation Analysis

The breakup based on design includes self-amplifying mRNA and conventional non-amplifying mRNA. Self-amplifying RNA (saRNA) vaccines utilize a self-replicating RNA platform to produce immune responses in the body. The RNA vaccines aim to stimulate the immune system to defend against specific pathogens. However, RNA vaccines use genetic material, specifically, messenger RNA, instead of using inactivated viruses, and instruct cells to produce a protein.

The detailed technological data will be provided for all specified segments classified in this report.

mRNA Cancer Therapeutics Patent Jurisdiction Analysis

The United States is one of the leading jurisdictions for mRNA cancer therapeutics patents, having around 101,000+ patents. The presence of major pharmaceutical companies, well-established healthcare infrastructure, advanced research and development activities and strong legal framework contributes to the patent landscape significantly.

Patent Profile of Key Companies

Among the players with mRNA cancer therapeutics patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

Pfizer, Inc.

Pfizer, Inc. founded in 1849 and headquartered in the United States is a global pharmaceutical company engaged in the development of medicines and vaccines in multiple therapeutic areas including cancer, cardiovascular diseases, and neurology among others. Pfizer is developing innovations in mRNA-based technologies for oncology with vaccine development programs for flu and shingles, along with respiratory combination vaccines.

Novartis AG

Novartis AG, founded in 1996 is headquartered in Switzerland. It is a global pharmaceutical company, engaged i...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other companies include Genentech Inc., Immatics Biotechnologies Gmbh, and Modernatx Inc., among others.

Reasons to Purchase this Report

The mRNA cancer therapeutics patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by -

• Competitive Advantage: The landscape reveals the market leaders, potential partners and innovators and also makes it understandable which companies have important patents in this field of mRNA cancer therapeutics.

• Innovation Insights: The patent analysis reveals new innovations and technologies in mRNA cancer therapeutics industry.

• Market Positioning: Companies with strong patent portfolios gain a competitive advantage because their intellectual property assets differentiate their products. Understanding their intellectual property strategy reveals the market position of new entrants and potential barriers to entry.

• Risk Assessment: In technology-intensive fields such as mRNA cancer therapeutics, risks of IP infringement are common. Analyzing patent landscapes helps companies assess risk, develop mitigation strategies, and inform licensing, partnering, and acquisition decisions.

Key Questions Answered in the mRNA Cancer Therapeutics Patent Landscape Report

• Who are the key players in the mRNA cancer therapeutics patent landscape?
• How is the patent portfolio distributed geographically?
• What are the emerging trends in mRNA cancer therapeutics patents?
• How has the patent landscape evolved over time?
• What are the strategic insights for market players and investors?
• What is the technological focus of patents in the mRNA cancer therapeutics industry?
• How do patent strategies impact competitive advantage?
• What are the implications of patent filings in mRNA cancer therapeutics?
• What are the challenges and opportunities in the mRNA cancer therapeutics patent landscape?
• What are the regulatory and legal considerations?
• What technological innovations have recently emerged in mRNA cancer therapeutics?

Related Reports

Global Cancer Immunotherapy Market

Global Cancer Vaccines Market

Global Immunotherapy Drugs Market

Global Monoclonal Antibodies Market